BioBridgeXAll companies

Transcode Therapeutics, Inc.

Pharmaceutical company · Boston, Massachusetts, United States · Nasdaq: RNAZ

Transcode Therapeutics, Inc. is a pharmaceutical company headquartered in Boston, Massachusetts, United States. Its shares trade on Nasdaq under the ticker RNAZ. It has received 3 US government small-business research awards (SBIR/STTR) from health agencies, $4.3 million in total, most recently in 2024. It has reported private securities offerings to the US SEC, most recently $8 million sold in a notice filed in 2024.

Profile compiled from public records. Is this your company? Request a correction or update

Transcode Therapeutics at a glance

Typepharmaceutical company
HeadquartersBoston, Massachusetts, United States
Stock listingNasdaq: RNAZ
SEC industryPharmaceutical Preparations
Employees (per SBIR records)2
SEC CIK1829635

What does Transcode Therapeutics do?

US government research funding

3 SBIR/STTR small-business research awards from US health agencies, $4.3 million in total (2021 to 2024). NIH funding came from the National Cancer Institute.

Private fundraising reported to the SEC

1 Form D notice; the most recent reported $8 million sold (2024).

Frequently asked questions about Transcode Therapeutics

Where is Transcode Therapeutics headquartered?

Transcode Therapeutics, Inc. is headquartered in Boston, Massachusetts, United States.

What does Transcode Therapeutics do?

Transcode Therapeutics, Inc. is a pharmaceutical company. Its SEC industry classification is Pharmaceutical Preparations.

Is Transcode Therapeutics a public company?

Yes. Transcode Therapeutics, Inc. trades on Nasdaq under the ticker RNAZ.

Similar companies

Need a CRO or CDMO for your next study?

Compare transparent quotes from research and manufacturing partners, then contract once. Free for buyers.

Compare quotes

Sources

Location data: GeoNames (geonames.org), CC BY 4.0.

Last updated 2026-09-23.